logo
Transat bets on Caribbean, Europe as travellers spurn U.S.

Transat bets on Caribbean, Europe as travellers spurn U.S.

CTV News12-06-2025
People look on as an Air Transat plane takes off at Trudeau in Montreal, Sunday, June 11, 2023. THE CANADIAN PRESS/Graham Hughes
MONTREAL — Transat A.T. Inc. hopes to turn Canadians' aversion to U.S. travel into a boon as it bets on new routes to the Caribbean, Mexico and Europe rather than destinations in the land of Donald Trump.
Chief executive Annick Guérard made the case Thursday for a winter schedule that includes fresh flights between Toronto and Guyana, Fredericton and Cancun, Mexico, and Quebec City and Martinique.
'We are taking advantage of the shift in demand from the U.S. to the Caribbean and Mexican markets by offering new exclusive routes,' Guérard told analysts on a conference call to discuss the company's latest results.
As Canadians turn away from their southern neighbour amid a trade war and '51st state' threats from the U.S. president, they've looked also to Europe for sun-splashed getaways.
Air Transat will extend routes to the port cities of Bordeaux, France, and Valencia, Spain, into the winter, the CEO said, while steering clear of the U.S. except for a handful of routes.
The number of Air Transat flights slated to take off from Canada to the U.S. this December is down 13 per cent year-over-year, according to aviation data firm Cirium. This month, the figure is down 36 per cent compared with June 2024.
Whether Air Transat's new routes will turn a profit remains to be seen.
In its latest quarter, Transat, which owns the airline, reported losses of $22.9 million, though the hit marked a major improvement from its $54.4-million loss in the same period a year earlier.
Several hurdles now confront the carrier, including competition, frugal customers and a diminished fleet.
'We've seen a little bit of shift as well from some players on the European destinations, creating downward pressure on pricing for this upcoming summer,' Guérard said, noting that Air Transat is not the only airline to ramp up transatlantic trips.
'Looking at the past weeks, we can see that bookings have been soft in Europe. With the uncertainty in the market — the economic environment — this is a little bit what we were expecting.'
Some of that downturn owes to more last-minute booking trends.
'People tend to wait and see what's going to happen — if people are going to keep their jobs, how the economy is going to move forward.'
Transat also continues to deal with fallout from the recall of turbofans for inspection and repair by enginemaker Pratt & Whitney. Air Transat, one of many airlines hit by the recall, has grounded at least a half-dozen planes as a result.
Guérard said she expects six or seven jets — up to 16 per cent of the 43-plane fleet — to remain out of commission through the year.
'We don't think that this situation will be settled before 2027,' chief financial officer Jean-François Pruneau said.
On the plus side, Pratt & Whitney paid Transat $20 million in compensation in its second quarter.
Despite notching a loss, the company boosted year-over-year revenues by six per cent to $1.03 billion in the three months ended April 30.
Guérard said higher revenue per seat, lower fuel expenses, tight cost control and the compensation from Pratt and Whitney helped it come closer to breaking even.
The Montreal-based company also increased adjusted net earnings to 12 cents per share in the quarter versus a loss of $1.21 per share a year earlier. The outcome soared above analysts' expectations of a loss of 92 cents per share, according to financial markets firm LSEG Data & Analytics.
Last week, Transat announced a deal to reduce its total debt with a federal Crown corporation by more than half to $334 million. Most of that reduction is due to about $380 million of debt forgiven under the agreement in principle.
This report by The Canadian Press was first published June 12, 2025.
By Christopher Reynolds
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Independent review of North Shore Wastewater Treatment Plant overruns on hold
Independent review of North Shore Wastewater Treatment Plant overruns on hold

CTV News

time28 minutes ago

  • CTV News

Independent review of North Shore Wastewater Treatment Plant overruns on hold

The North Shore Wastewater Treatment Plant is seen during construction in Fall 2020. (Metro Vancouver) Metro Vancouver has put its independent review of the massively over-budget North Shore Wastewater Treatment Plant project on hold while it litigates the issue with the project's former contractor. The regional district announced the decision on Friday, saying it is 'not in the public interest' to continue the review while its lawsuit against Acciona Wastewater Solutions LP – and the company's counterclaim against Metro Vancouver – are before the courts. The litigation is currently scheduled to go to trial in March 2027. 'After careful consideration, the board has decided the public interest is best served by resolving the legal dispute with the previous contractor before undertaking the review,' said Burnaby Mayor Mike Hurley, chair of Metro Vancouver's Board of Directors, in a statement Friday. The board first launched the independent review process in June 2024, hiring retired judge John J.L. Hunter to 'develop the scope and terms of reference for the review and the process of selecting an independent, qualified reviewer,' Metro Vancouver's statement explains. Hunter has since died, and his role is now being filled by Randal Kaardal, a senior litigator at his company Hunter Litigation Chambers. Before his death, Hunter selected the MWGK Independent Review Team to conduct the review. In the Metro Vancouver statement, Kaardal said delaying the review until the conclusion of the court process will result in more information being available to the reviewer. 'The litigation is a public process, and once the dispute with the former contractor has been resolved, the Metro Vancouver board and the reviewer would be in a better position to complete a review on any outstanding questions,' Kaardal said. Metro Vancouver dismissed Acciona in October 2021, claiming that the company had 'abandoned' the project, a claim Acciona says is not true. The two sides are currently suing each other in B.C. Supreme Court, with Acciona alleging that Metro Vancouver has refused to pay it more than $100 million for work it completed on the site, and that the regional district made more than 1,000 requests for project modifications that led directly to the project's ballooning cost. For its part, Metro Vancouver says Acciona failed to meet project timelines and left it with 'no choice' but to cancel the contract. Acciona blames the delays on Metro Vancouver's 'flawed design' and 'interference' with the project. Originally budgeted at roughly $500 million and expected to be completed by 2020, the North Shore Wastewater Treatment Plant project is now moving forward with a different contractor at a cost of $3.86 billion – more than seven times the original budget. The anticipated completion date is now sometime in 2030.

AstraZeneca's Osimertinib Study: A Potential Game-Changer for NSCLC Treatment
AstraZeneca's Osimertinib Study: A Potential Game-Changer for NSCLC Treatment

Globe and Mail

timean hour ago

  • Globe and Mail

AstraZeneca's Osimertinib Study: A Potential Game-Changer for NSCLC Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a study titled 'Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France' to evaluate the effectiveness of osimertinib in treating locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating EGFR mutations. The study aims to assess the 36-month overall survival rate, patient characteristics, disease progression, treatment patterns, and quality of life. The intervention being tested is osimertinib, a drug used as a first-line treatment for NSCLC patients with specific genetic mutations. It is designed to target and inhibit the growth of cancer cells. This observational study employs a multicenter design, combining a cross-sectional survey and a prospective cohort model. It focuses on real-life treatment scenarios to gather comprehensive data on patient outcomes and treatment efficacy. The study began on May 12, 2021, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and ensuring timely analysis of the data collected. The study's findings could significantly impact AstraZeneca's stock performance by demonstrating the effectiveness of osimertinib, potentially boosting investor confidence. It also positions AstraZeneca competitively within the oncology market, particularly against other companies developing treatments for NSCLC. The study is ongoing, with further details available on the ClinicalTrials portal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store